Etiology-dependent molecular mechanisms in human hepatocarcinogenesis

Hepatology

Volumn 47, Issue 2, 2008, Pages 511-520

  Schlaeger, Christof ^a   Longerich, Thomas ^b   Schiller, Claudia ^b   Bewerunge, Peter ^a   Mehrabi, Arianeb ^b   Toedt, Grischa ^a   Kleeff, Jörg ^b   Ehemann, Volker ^b   Eils, Roland ^a   Lichter, Peter ^a   Schumacher, Peter ^b   Radlwimmer, Bernhard ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADOLESCENT; ADULT; AGED; ALCOHOL CONSUMPTION; APOPTOSIS; ARTICLE; BASE PAIRING; CANCER CELL CULTURE; CELL STRAIN HEPG2; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CHRONIC HEPATITIS; CONTROLLED STUDY; EEF1A2 GENE; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE OVEREXPRESSION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MDM4 GENE; ONCOGENE MYC; PRIORITY JOURNAL; PROGNOSIS; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE AMPLIFICATION; GENE DELETION; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE DELETION;

EID: 39549099942     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22033     Document Type: Article

References (42)

1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-285.
2. Badvie S. Hepatocellular carcinoma. Postgrad Med J 2000;76:4-11.
3. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140.
4. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-687.
5. Moinzadeh P, Breuhahn K, Stutzer H, Schirmacher P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade - results of an explorative CGH meta-analysis. Br J Cancer 2005;92:935-941.
6. Dries V, von Both I, Muller M, Gerken G, Schirmacher P, Odenthal M, et al. Detection of hepatitis C virus in paraffin-embedded liver biopsies of patients negative for viral RNA in serum. HEPATOLOGY 1999;29:223-229.
7. van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS, et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 2003;163:1033-1043.
8. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997;20:399-407.
9. Zielinski B, Gratias S, Toedt G, Mendrzyk F, Stange DE, Radlwimmer B, et al. Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. Genes Chromosomes Cancer 2005;43:294-301.
10. Thuerigen O, Schneeweiss A, Toedt G, Warnat P, Hahn M, Kramer H, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 2006;24:1839-1845.
11. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
12. Smyth GK, Yang YH, Speed T. Statistical issues in cDNA microarray data analysis. Methods Mol Biol 2003;224:111-136.
13. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004;20:3413-3422.
14. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-5121.
15. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
16. Longerich T, Breuhahn K, Odenthal M, Petmecky K, Schirmacher P. Factors of transforming growth factor beta signalling are co-regulated in human hepatocellular carcinoma. Virchows Arch 2004;445:589-596.
17. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. [in German] Pathologe 1987;8:138-140.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
19. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-279.
20. Patil MA, Gutgemann I, Zhang J, Ho C, Cheung ST, Ginzinger D, et al. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis 2005;26:2050-2057.
21. Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. HEPATOLOGY 2003;38:1242-1249.
22. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
23. Iizuka N, Tsunedomi R, Tamesa T, Okada T, Sakamoto K, Hamaguchi T, et al. Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus. J Cancer Res Clin Oncol 2006; 132:473-481.
24. Fults D, Pedone C, Dai C, Holland EC. MYC expression promotes the proliferation of neutal progenitor cells in culture and in vivo. Neoplasia 2002;4:32-39.
25. Dvorak P, Dvorakova D, Hampl A. Fibroblast growth factor signaling in embryonic and cancer stem cells. FEBS Lett 2006;580:2869-2874.
26. Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factot 19 in skeletal muscle of transgenic mice. Am J Pathol 2002;160:2295-2307.
27. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002;143:1741-1747.
28. Desnoyers LR, Pai R, Ferrando RE, Hötzel K, Le T, Ross J, et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2007; doi: 10.1038/sj.onc.1210623. Available at: http://www.nature.com/onc/index.html.
29. Riemenschneider MJ, Knobbe CB, Reifenberger G. Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int J Cancer 2003;104:752-757.
30. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A 2006;103:3232-3237.
31. Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, et al. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 2006;9:273-285.
32. Lechel A, Holstege H, Begus Y, Schienke A, Kamino K, Lehmann U, et al. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease. Gastroenterology 2007;132:1465-1475.
33. Gray JW, Collins C, Henderson IC, Isola J, Kallioniemi A, Kallioniemi OP, et al. Molecular cytogenetics of human breast cancer. Cold Spring Harb Symp Quant Biol 1994;59:645-652.
34. Aust DE, Muders M, Kohler A, Schmidt M, Diebold J, Muller C, et al. Prognostic relevance of 20q13 gains in sporadic colorectal cancers: a FISH analysis. Scand J Gastroenterol 2004;39:766-772.
35. Iwabuchi H, Sakamoto M, Sakunaga H, Ma YY, Carcangiu ML, Pinkel D, et al. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res 1995;55:6172-6180.
36. Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 2002;31:301-305.
37. Li R, Wang H, Bekele BN, Yin Z, Caraway NP, Katz RL, et al. Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene 2006;25:2628-2635.
38. Tomlinson VA, Newbery HJ, Wray NR, Jackson J, Larionov A, Miller WR, et al. Translation elongation factoi eEF1A2 is a potential oncoprotein mat is overexpressed in two-thirds of breast tumours. BMC Cancer 2005;5:113.
39. Amiri A, Noei F, Jeganathan S, Kulkarni G, Pinke DE, Lee JM. eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration. Oncogene 2007;26:3027-3040.
40. Jeganathan S, Lee JM. Binding of elongation factor eEF1A2 to phosphatidylinositol 4-kinase beta stimulates lipid kinase activity and phosphatidylinositol 4-phosphate generation. J Biol Chem 2007;282:372-380.
41. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targers. HEPATOLOGY 2007;45:42-52.
42. Chang R, Wang E. Mouse Translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress. J Cell Biochem 2007;100:267-278.